Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTI-DA4
- Development stage
- Preclinical
- Lead developer
- ProteoTech
- Modality
- Small Molecules
01
Overview
PTI-DA4 is a small molecule therapeutic developed by ProteoTech designed to target the tau protein for the treatment of neurodegenerative tauopathies, including Alzheimer's Disease and Progressive Supranuclear Palsy (PSP). The compound is intended to modulate or inhibit the pathological aggregation and toxicity of tau proteins, which are key drivers of neuronal dysfunction in these conditions. As of 2014, the program was in the preclinical stage of development and had received Small Business Innovation Research (SBIR) funding. The mechanism of action involves direct interaction with tau to prevent the formation of toxic aggregates.
- Other names
- PTI-DA4 (tau compound)
Beyond the preview
Go deeper on PTI-DA4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTI-DA4.